Safety and perception: What are the greatest enemies of HPV vaccination programmes?

作者: Paolo Bonanni , Beatrice Zanella , Francesca Santomauro , Chiara Lorini , Angela Bechini

DOI: 10.1016/J.VACCINE.2017.05.071

关键词: MedicineAdverse effectFamily medicinePapillomavirus VaccinesComplex regional pain syndromeVaccinationDiseasePopulationPsychological interventionImmunologyHPV vaccines

摘要: Vaccines stimulate a person's immune system to produce an adequate reaction against specific infectious agent; i.e. the person is protected from that disease without having get it first. As vaccines are administrated healthy subjects, they held highest standards of safety. Regarding human papillomavirus (HPV) vaccines, at present three prophylactic licensed (bivalent HPV 16/18, quadrivalent 6/11/16/18 and nonovalent 6/11/16/18/31/33/45/52/58 vaccine). Pre- post-licensure studies (i.e. not yet for vaccine) confirm generally safe well-tolerated, site injections symptoms most common adverse events (AEs) reported, pain frequently referred local symptom. Serious AEs rare associated with severe sequelae, least no vaccine-related deaths have occurred. Despite these scientific evidences, still difficult explain population importance good vaccination programme. There many determinants hesitancy which represent barrier must be overcome in order increase vaccine coverage, including psychological reactions, religious or cultural aspects, fear possible (demyelinating diseases, Complex Regional Pain Syndrome - CRPS, Postural Orthostatic Tachycardia POTS). A weak communication strategy suffers due spread unverified news by media websites may lead failure Such situation happened Japan (2013), great number women remain vulnerable HPV-related cancers. In resolve issues around acceptance, necessary use strategies. Multicomponent dialogue-based interventions seem effective, especially if language used, customized according programme target.

参考文章(39)
Alain Luxembourg, Darron Brown, Celine Bouchard, Anna R Giuliano, Ole-Erik Iversen, Elmar A Joura, Mary E Penny, Jaime A Restrepo, Josefina Romaguera, Roger Maansson, Erin Moeller, Michael Ritter, Joshua Chen, Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Human Vaccines & Immunotherapeutics. ,vol. 11, pp. 1313- 1322 ,(2015) , 10.1080/21645515.2015.1012010
Julia ML Brotherton, Human papillomavirus vaccination: Where are we now? Journal of Paediatrics and Child Health. ,vol. 50, pp. 959- 965 ,(2014) , 10.1111/JPC.12627
Nikolai Madrid Scheller, Henrik Svanström, Björn Pasternak, Lisen Arnheim-Dahlström, Karin Sundström, Katharina Fink, Anders Hviid, Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. ,vol. 313, pp. 54- 61 ,(2015) , 10.1001/JAMA.2014.16946
Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Celine Bouchard, Constance Mao, Jesper Mehlsen, Edson D Moreira Jr, Yuen Ngan, Lone Kjeld Petersen, Eduardo Lazcano-Ponce, Punnee Pitisuttithum, Jaime Alberto Restrepo, Gavin Stuart, Linn Woelber, Yuh Cheng Yang, Jack Cuzick, Suzanne M Garland, Warner Huh, Susanne K Kjaer, Oliver M Bautista, Ivan SF Chan, Joshua Chen, Richard Gesser, Erin Moeller, Michael Ritter, Scott Vuocolo, Alain Luxembourg, None, A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women The New England Journal of Medicine. ,vol. 372, pp. 711- 723 ,(2015) , 10.1056/NEJMOA1405044
FREDERICK VARRICCHIO, JOHN ISKANDER, FRANK DESTEFANO, ROBERT BALL, ROBERT PLESS, M. MILES BRAUN, ROBERT T. CHEN, Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatric Infectious Disease Journal. ,vol. 23, pp. 287- 294 ,(2004) , 10.1097/00006454-200404000-00002
S. J. W. Evans, P. C. Waller, S. Davis, Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports Pharmacoepidemiology and Drug Safety. ,vol. 10, pp. 483- 486 ,(2001) , 10.1002/PDS.677
Heinz-J Schmitt, Robert Booy, Robert Aston, Pierre Van Damme, R Fabian Schumacher, Magda Campins, Carlos Rodrigo, Terho Heikkinen, Catherine Weil-Olivier, Adam Finn, Per Olcén, David Fedson, Heikki Peltola, How to optimise the coverage rate of infant and adult immunisations in Europe BMC Medicine. ,vol. 5, pp. 11- 11 ,(2007) , 10.1186/1741-7015-5-11
Caitlin Jarrett, Rose Wilson, Maureen O’Leary, Elisabeth Eckersberger, Heidi J. Larson, Strategies for addressing vaccine hesitancy – A systematic review☆ Vaccine. ,vol. 33, pp. 4180- 4190 ,(2015) , 10.1016/J.VACCINE.2015.04.040
R CHEN, S RASTOGI, J MULLEN, S HAYES, S COCHI, J DONLON, S WASSILAK, The Vaccine Adverse Event Reporting System (VAERS). Vaccine. ,vol. 12, pp. 542- 550 ,(1994) , 10.1016/0264-410X(94)90315-8
Melinda Wharton, Vaccine safety: current systems and recent findings. Current Opinion in Pediatrics. ,vol. 22, pp. 88- 93 ,(2010) , 10.1097/MOP.0B013E3283350425